AstraZeneca (AZN) Receives Buy Rating from Deutsche Bank

Share on StockTwits

Deutsche Bank reissued their buy rating on shares of AstraZeneca (LON:AZN) in a report published on Tuesday, September 25th, MarketBeat reports. The firm currently has a GBX 6,000 ($78.40) target price on the biopharmaceutical company’s stock.

AZN has been the subject of a number of other reports. Barclays reissued an overweight rating and issued a GBX 6,600 ($86.24) price objective (up from GBX 6,500 ($84.93)) on shares of AstraZeneca in a research report on Friday, August 10th. Credit Suisse Group set a GBX 5,900 ($77.09) price objective on shares of AstraZeneca and gave the company a buy rating in a research report on Friday, July 27th. Liberum Capital reissued a hold rating on shares of AstraZeneca in a research report on Friday, August 31st. JPMorgan Chase & Co. set a GBX 5,800 ($75.79) price objective on shares of AstraZeneca and gave the company a buy rating in a research report on Friday, July 20th. Finally, Goldman Sachs Group set a GBX 4,080 ($53.31) price objective on shares of AstraZeneca and gave the company a sell rating in a research report on Friday, August 31st. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the company. AstraZeneca presently has an average rating of Hold and a consensus price target of GBX 5,700.70 ($74.49).

LON AZN traded down GBX 70 ($0.91) during trading hours on Tuesday, hitting GBX 5,546 ($72.47). The company had a trading volume of 2,077,869 shares, compared to its average volume of 2,310,000. AstraZeneca has a fifty-two week low of GBX 4,260 ($55.66) and a fifty-two week high of GBX 5,520 ($72.13).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Read More: Investing in Growth Stocks

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.